CAR-T Meeting 2024 | Epitope editing enables the use of novel immunotherapies for AML
Pietro Genovese, PhD, Harvard Medical School, Boston, MA, discusses the use of epitope editing to improve outcomes and the safety of novel immunotherapies in patients with acute myeloid leukemia (AML). Leukemia blasts and healthy hematopoietic stem cells often share the targets of novel immunotherapies, meaning that on-target off-tumor toxicity is an ongoing challenge. By engineering the epitope on the surface of healthy cells, a new variant of the same protein can be generated while preserving functionality, and the cell is no longer recognized by the immunotherapy treatment. Dr Genovese highlights that epitope editing may provide an improved strategy for treating AML when combined with stem cell transplantation. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
